Total lipid management and cardiovascular disease in the dyslipidemia international study

Cardiology (Switzerland)

Volumn 125, Issue 3, 2013, Pages 154-163

  Ferrières, Jean ^a   Amber, Vian ^b,c   Crisan, Oliviu ^d   Chazelle, François ^e   Jünger, Claus ^f   Wood, David ^b  

^a CHU RANGUEIL   (France)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c Merck Sharp & Dohme Limited   (United Kingdom)

^d Merck Sharpe and Dohme   (France)

^e MERCK RESEARCH LABORATORIES   (United States)

^f UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cardiovascular disease; Cholesterol; Dyslipidemia; Dyslipidemia International Study; Epidemiological study; Statin

Indexed keywords

ATORVASTATIN; BILE ACID SEQUESTRANT; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

AGED; ARTICLE; ATHEROSCLEROSIS; AUSTRIA; BODY MASS; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DENMARK; DIASTOLIC BLOOD PRESSURE; DYSLIPIDEMIA; FEMALE; FRANCE; GERMANY; GREECE; HEART FAILURE; HUMAN; IRELAND; ISCHEMIC HEART DISEASE; ISRAEL; ITALY; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NORWAY; OBSERVATIONAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PORTUGAL; PREVALENCE; PRIORITY JOURNAL; SEDENTARY LIFESTYLE; SPAIN; SWEDEN; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM; WAIST CIRCUMFERENCE;

EID: 84878360109     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000348859     Document Type: Article

References (32)

1. Nichols M, Townsend N, Luengo-Fernandez R, Leal J, Gray A, Scarborough P, Rayner M: European Cardiovascular Disease Statistics 2012. European Heart Network, Brussels, European Society of Cardiology, Sophia Antipolis.
2. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Rosamond WD, Sorlie PD, Stafford RS, Turan TN, Turner MB, Wong ND, Wylie-Rosett J; on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011;123:e18-e209.
3. Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
4. Poirier P, Giles TD, Bray GA, et al; American Heart Association; Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism: Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006; 113: 898-918.
5. Perk J, De Backer G, Gohlke H, et al: European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012; 33: 1635-1701.
6. Graham I, Atar D, Borch-Johnsen K, et al: European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14(suppl 2):S1-S113.
7. Smith SC Jr, Allen J, Blair SN, et al: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. J Am Coll Cardiol 2006; 47: 2130-2139.
8. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
9. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, et al: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117-125.
10. Grundy SM, Cleeman JI, Merz CN, et al; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239
11. erratum in Circulation 2004; 110: 763.
12. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice: European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007; 28: 2375-2414.
13. Shah PK, Kaul S, Nilsson J, Cercek B: Exploiting the vascular protective effects of highdensity lipoprotein and its apolipoproteins: an idea whose time for testing is coming. Part I. Circulation 2001; 104: 2376-2383.
14. Gotto AM Jr: High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J 2002; 144(suppl 6):S33-S42.
15. Barter PJ, Puranik R, Rye KA: New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease. Curr Cardiol Rep 2007; 9: 493-498.
16. McBride P: Triglycerides and risk for coronary artery disease. Curr Atheroscler Rep 2008; 10: 386-390.
17. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group: Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373: 929-940.
18. Van Ganse E, Laforest L, Burke T, Phatak H, Souchet T: Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study. Clin Ther 2007; 29: 1671-1681.
19. Phatak H, Wentworth C, Sazonov V, Burke T: Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general practice. Atherosclerosis 2009; 202: 225-233.
20. Suárez C, Maiques A, Ambegaonkar BM, et al: Attainment of multiple recommended lipid levels following lipid modifying treatment in high-risk patients. PRIMULA Study, Spain (abstract). ISPOR 11th Annual European Congress, Athens, November 2008.
21. Gitt A, Drexel H, Feely J, et al: Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur J Prev Cardiol 2012; 19: 221-230.
22. Maron DJ, Fazio S, Linton MF: Current perspectives on statins. Circulation 2000; 101: 207-213.
23. Roberts WC: The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997; 80: 106-107.
24. Hobbs R, Erhardt L: Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassuring European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract 2002; 19: 596-604.
25. Wolf-Maier K, Cooper RS, Kramer H, et al: Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10-17.
26. Thambidorai SK, Deshmukh AR, Walters RW, Turner PD, Monaghan MS, Mooss AN, Hunter CB, Esterbrooks DJ, Mohiuddin SM: Impact of statin use on heart failure mortality. Int J Cardiol 2011; 147: 438-443.
27. Khush KK, Waters DD, Bittner V, Deedwania PC, Kastelein JJP, Lewis SJ, Wegner NK: Effect of high-dose atorvastatin on hospitalizations for heart failure-subgroup analysis of the Treating to New Targets (TNT) study. Circulation 2007; 115: 576-583.
28. Kjekshus J, Apetrei E, Barrios V, et al: Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-2261.
29. Yamada T, Node K, Mine T, Morita T, Kioka H, Tsukamoto Y, Tamaki S, Masuda M, Fukunami M: Long-term effect of atorvastatin on neurohormonal activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study. Am Heart J 2007; 153: 1055-1058.
30. Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, et al: Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231-1239.
31. Kotseva K, Wood D, de Backer G, et al: EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil 2010; 17: 530-540.
32. Sharma M, Ansari MT, Abou-Setta AM, et al: Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann Intern Med 2009; 151: 622-630.